NTRK2 and schizophrenia: The ability of BDNF-TrkB signaling to sustain or enhance neuroplasticity altered in schizophrenia might explain the improved therapeutic efficacy of glutamatergic antipsychotics compared to currently available monoaminergic antipsychotics in alleviating negative and cognitive symptoms of schizophrenia.